Market Overview
The erectile dysfunction market is making significant progress backed by the mounting patient awareness as well as education level. Expanding geriatric patient pool, surge in a number of lifestyle diseases and the social stigma associated with ED could also foster further market growth. Brand loyalty coupled with rising acceptance of established brands such as Viagra, Levitra/Staxyn and Cialis will also add to the market value in the ensuing years.
The erectile dysfunction drugs industry is highly consolidated and is brimming with major companies that are actively involved in fierce rivalry. Generics are anticipated to bolster industrial growth during the review period. Moreover, mergers, post-patent expiration, collaborations and acquisitions activities, along with regional expansion will enhance the competitive quotient between players over the analysis period.
Market Research Future (MRFR) believes that the erectile dysfunction drugs market can record a growth rate of 3.5% between 2019 and 2025. MRFR also conjectures that the market value by 2025 should be USD 2930 million.
Mental health issues and stress are known for triggering the erectile dysfunction condition. Psychological and physical challenges can also result in erectile dysfunction. Sedentary lifestyle, alcohol consumption and smoking are a few other exacerbating factors. The UK Health Centre reports that close to 50 percent of total men in the country smoke a complete packet of cigarette in a day and are therefore, at a higher risk of developing ED.
Regional Study
The key markets for erectile dysfunction drugs are the Americas, APAC or Asia Pacific, MEA or Middle East & Africa and Europe.
Americas stands as the biggest market for erectile dysfunction drugs, headed by the United States. The expanding elderly population struggling with the condition has been favorable for the American market, since ED is quite common among men aged above 40. Availability of a wide array of erectile dysfunction drugs via online channels and over the counter (OTC) should further foster the market expansion rate. The prevalence of online pharmacy stores has grown immensely in the region, given that most of the patients are hesitant to visit a retail pharmacy store for purchasing the drugs.
The Asia Pacific market can progress at the fastest rate in the coming years, in view of the burgeoning geriatric population prone to ED and the increasing availability of a variety of generic drugs. Government-led reforms as well as public awareness programs in a number of emerging countries like India and China can push the growth trajectory of the regional market. Economic growth, development of the healthcare infrastructure, and rapid expansion of the target population are a few other significant growth boosters in the APAC market. Novel molecule combinations paired with drug delivery methods like using pellets and creams with higher efficacy as well as performance should be a lucrative opportunity for erectile dysfunction drugs manufacturers in the region. Thriving generic drugs sector along with the social stigma attached to the condition will encourage market growth in subsequent years.
Request Free Sample: https://www.marketresearchfuture.com/sample_request/1313
Segmental Status
The global market for erectile dysfunction drugs has been considered for drug and end-user.
The major drugs available in the market for ED are cialis (tadalafil), viagra (sildenafil citrate), stendra/spedra (avanafil), staxyn/levitra (vardenafil), vitaros (alprostadil cream), zydena (udenafil), and more. The highest demand is witnessed by the viagra drug and therefore, the segment is on track to secure the leading position in the market. Viagra has been the first drug to ever achieve the Food and Drug Administration approval for oral consumption to treat erectile dysfunction. The Viagra drug was introduced by Pfizer in 1998 and has been ruling the global market ever since. Cialis drug, on the other hand, has been growing at a swift rate in the global industry, since it provides an erection for a longer period compared to viagra, which is close to 18 hours and above whereas viagra only ensures erection for 4 to 6 hours.
Major end users in the global market are retail pharmacy, online pharmacy and hospital pharmacy. Retail pharmacy should be the top segment in the years ahead, because of the high availability of a number of such stores. Hospital pharmacy will emerge as the fastest expanding segment in the near future, owing to the widening patient pool being admitted in hospitals.
Browse Complete Report: https://www.marketresearchfuture.com/reports/erectile-dysfunction-drugs-market-1313
Major Firms
Some of the most renowned vendors in the market for erectile dysfunction drugs include Apricus Biosciences Inc., Cristalia Produtos Quimicos Farmaceuticos Ltd., Vivus, Inc., Pfizer, Inc., S.K. Chemicals Co. Ltd., Bayer AG, Teva Pharmaceutical Industries Ltd, Dong-A Pharmaceutical Co. Ltd., Meda Pharmaceuticals, Inc., Eli Lilly and Company, to name a few.
CURR has been granted the USFDA approval for Investigational New Drug application of its latest CUREfilm Blue, which is an oral soluble film of sildenafil citrate that treats erectile dysfunction. CUREfilm Blue makes use of the company’s proprietary rapidly dissolving system of drug delivery, called CUREfilm, for delivering the active pharmaceutical ingredient sildenafil citrate.
No comments:
Post a Comment